Sun Da-wei, Zhang Ying-yi, Sun Xiao-dong, Chen Yu-guo, Qiu Wei, Ji Min, Lv Guo-yue
Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Jilin University, Changchun 130021, Jilin Province, China.
Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Clin Chim Acta. 2015 Aug 25;448:161-9. doi: 10.1016/j.cca.2015.06.027. Epub 2015 Jul 9.
Although many studies have investigated the relationship between cytokeratin 19 (CK-19) and hepatocellular carcinoma (HCC), the prognostic value of CK-19 in HCC remains inconclusive.
Eligible studies were sought in PubMed, Embase, Web of Science, Cochrane Library and Wanfang databases. Pooled hazard ratios (HRs) and odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated.
17 studies with 2943 patients were included in this meta-analysis. Meta-analysis results showed that CK-19 over-expression was significantly associated with overall survival (OS) (HR=1.60, 95% CI: 1.32-1.93, univariate analysis; HR=2.25, 95% CI: 1.79-2.83, multivariate analysis) and disease-free survival (DFS) (HR=1.68, 95% CI: 1.35-2.10, univariate analysis; HR=1.97, 95% CI: 1.54-2.53, multivariate analysis). Meanwhile, CK-19 over-expression was also correlated with decreased 1-year OS rate (OR=0.32, 95% CI: 0.21-0.50), 5-year OS rate (OR=0.44, 95% CI: 0.14-0.87) and 1-year DFS rate (OR=0.51, 95% CI: 0.34-0.76), but not with 5-year DFS rate (OR=0.62, 95% CI: 0.35-1.10). These results suggested that CK-19 over-expression was significantly associated with poor survival rate and early tumor recurrence rate in HCC patients.
CK-19 can serve as an indicator of poor prognosis as well as a novel target for treatment in HCC.
尽管许多研究已经调查了细胞角蛋白19（CK - 19）与肝细胞癌（HCC）之间的关系，但CK - 19在HCC中的预后价值仍无定论。
在PubMed、Embase、Web of Science、Cochrane图书馆和万方数据库中检索符合条件的研究。计算合并风险比（HRs）和比值比（ORs）以及相应的95%置信区间（CIs）。
本荟萃分析纳入了17项研究，共2943例患者。荟萃分析结果显示，CK - 19过表达与总生存期（OS）显著相关（HR = 1.60，95% CI：1.32 - 1.93，单因素分析；HR = 2.25，95% CI：1.79 - 2.83，多因素分析）和无病生存期（DFS）（HR = 1.68，95% CI：1.35 - 2.10，单因素分析；HR = 1.97，95% CI：1.54 - 2.53，多因素分析）。同时，CK - 19过表达还与1年总生存率降低（OR = 0.32，95% CI：0.21 - 0.50）、5年总生存率降低（OR = 0.44，95% CI：0.14 - 0.87）和1年无病生存率降低（OR = 0.51，95% CI：0.34 - 0.76）相关，但与5年无病生存率无关（OR = 0.62，95% CI：0.35 - 1.10）。这些结果表明，CK - 19过表达与HCC患者的低生存率和早期肿瘤复发率显著相关。
CK - 19可作为HCC预后不良的指标以及一种新的治疗靶点。
